HormonesResearch PaperOpen Access

Elamipretide Peptide Reverses Oocyte Aging and Restores Fertility in Older Females

A mitochondria-targeting peptide rescues egg quality and live birth rates in aged mice — and shows early promise in human oocytes.

Sunday, October 4, 2026 4 views
Published in Aging Cell
A microscope stage with a human oocyte visible through an eyepiece, surrounded by lab equipment and a researcher's gloved hands adjusting a microinjection needle

Summary

Age-related decline in egg quality contributes to reduced female fertility, with mitochondrial dysfunction playing an important role. Researchers tested elamipretide, a peptide that targets mitochondria, in aged female mice. Treatment increased litter size and improved both nuclear and cytoplasmic maturation of aged eggs. Metabolomic and transcriptomic findings implicated a vitamin B6–VEGF signaling axis. Elamipretide also improved maturation, fertilization and cleavage of aged human eggs studied in the laboratory and rescued the developmental competence of pig eggs under oxidative damage. These findings support further research, but do not establish a fertility treatment for women.

Detailed Summary

Age-related decline in egg (oocyte) quality is an important contributor to reduced female fertility. Advanced maternal age is associated with miscarriage, chromosomal abnormalities and fetal growth restriction. Mitochondrial dysfunction can contribute to oxidative stress, inadequate energy supply and meiotic abnormalities in aged oocytes. The introduction describes limitations such as poor targeting or bioavailability among existing experimental strategies. Elamipretide is a cell-penetrating tetrapeptide that accumulates in the inner mitochondrial membrane and binds cardiolipin.

The study examined elamipretide in aged female mice. The methods identify ICR mice, including 8-, 10- and 12-month-old females and young controls aged 6–8 weeks. The abstract reports that elamipretide administration increased litter size and ameliorated age-related oocyte-quality decline. The introduction also reports improved embryo quality in mice. The supplied excerpt does not specify the elamipretide dosing regimen or provide numerical effect sizes.

Metabolomic and transcriptomic profiling indicated substantial restoration of multiple biological processes in aged oocytes after elamipretide injection. Treatment improved both nuclear maturation, involving meiotic progression and chromosome separation, and cytoplasmic maturation, which prepares the egg for fertilization and development. These improvements were accompanied by enhanced cytoskeletal dynamics, mitochondrial metabolism and organelle reorganization.

The authors attribute the improvement in age-associated maturation defects to synergistic activation of a vitamin B6–VEGF axis. The excerpt does not provide the detailed metabolite comparisons or intervention results needed to assess the individual contributions of vitamin B6 and downstream signaling components.

The study also examined human and porcine oocytes. Human oocytes were collected from consenting patients undergoing ICSI cycles; eligibility included retrieval of at least two immature, germinal-vesicle-stage oocytes. The abstract reports significantly improved maturation, fertilization and cleavage of aged human oocytes with elamipretide. All resulting human embryos were used solely for research and were neither transferred nor cryopreserved for clinical use. Elamipretide also rescued the developmental competence of porcine oocytes exposed to oxidative damage.

These are animal and laboratory findings, not evidence of improved pregnancy or live-birth outcomes in treated women. The supplied excerpt does not establish the duration of benefit, optimal human dosing or long-term offspring safety. It also lacks numerical effect sizes, detailed statistical methods and human sample sizes, limiting assessment of the strength and clinical applicability of the findings.

Key Findings

  • Elamipretide administration increased litter size and ameliorated age-related oocyte-quality decline in aged mice.
  • Treatment improved both nuclear and cytoplasmic maturation of aged oocytes.
  • Improved maturation was accompanied by enhanced cytoskeletal dynamics, mitochondrial metabolism and organelle reorganization.
  • Metabolomic and transcriptomic profiling indicated restoration of multiple biological processes in aged oocytes.
  • The authors attribute the rescue of age-associated maturation defects to synergistic activation of a vitamin B6–VEGF axis.
  • Elamipretide significantly promoted maturation, fertilization and cleavage of aged human oocytes in laboratory experiments; resulting embryos were not transferred.
  • Elamipretide rescued the developmental competence of porcine oocytes under oxidative damage.

Methodology

The supplied methods describe ICR female mice aged 8, 10 and 12 months and young controls aged 6–8 weeks for oocyte collection. Mouse procedures included hormonal superovulation, oocyte culture, in vitro fertilization and culture to early embryonic stages. The abstract reports elamipretide injection and metabolomic and transcriptomic profiling, but the available excerpt does not specify the drug regimen or detailed statistical methods. Human oocytes were obtained with ethics approval and informed consent from ICSI patients with at least two GV-stage oocytes retrieved. All resulting human embryos were used solely for research and were neither transferred nor cryopreserved for clinical use. The abstract also describes experiments on porcine oocytes under oxidative damage.

Study Limitations

The evidence described comes from mouse experiments and laboratory studies of human and porcine oocytes. Human embryos were not transferred, so these experiments do not establish clinical pregnancy or live-birth benefits. The supplied excerpt does not provide the elamipretide dosing regimen, duration of benefit, numerical effect sizes, detailed statistical methods or human sample sizes. Long-term offspring safety and optimal dosing in women are not established by the available text. Conflicts of interest were not stated in the supplied excerpt.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: